Thermo Fisher Scientific (TMO) Cash from Investing Activities (2009 - 2026)

Thermo Fisher Scientific has reported Cash from Investing Activities for 18 years, with the latest figure at $164.0 million in Q2 2026.

• Cash from Investing Activities for Q2 2026 came in at $164.0 million, up 156.94% year-over-year; the trailing twelve-month figure through Jun 2026 was -$12.0 billion (down 175.07% YoY), and the FY2025 annual result was -$4.0 billion, up 30.71% from the prior year.
• Cash from Investing Activities climbed to $164.0 million in Q2 2026, from -$9.0 billion in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $891.0 million in Q4 2025 and troughed at -$9.0 billion in Q1 2026.
• A 5-year average of -$1.4 billion and a median of -$526.0 million in 2022 frame the typical range for Cash from Investing Activities.
• The widest annual swing landed in 2025, when Cash from Investing Activities surged 4355.0%; it then plunged 1600.38% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at -$525.0 million in 2022, then climbed by 28.38% to -$376.0 million in 2023, then surged by 105.32% to $20.0 million in 2024, then surged by 4355.0% to $891.0 million in 2025, then plunged by 81.59% to $164.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $164.0 million in Q2 2026, -$9.0 billion in Q1 2026, and $891.0 million in Q4 2025.